Topical and low-dose intravenous tranexamic acid in cyanotic cardiac surgery. (February 2017)

• Record Type: Journal Article
• Authors: Patel, Jigar; Prajapati, Mrugesh; Patel, Hardik; Gandhi, Hemang; Deodhar, Shilpa; Pandya, Himani
• Is Part Of: Asian cardiovascular & thoracic annals. Volume 25:Number 2(2017)
• Page Start: 118
• Page End: 122
• Publication Date: 2017-02
• Subjects: Heart defects -- congenital -- Antifibrinolytic agents -- Blood loss -- surgical -- Cardiopulmonary bypass -- Cyanosis -- Tranexamic acid; Heart -- Diseases -- Asia -- Periodicals; Heart -- Diseases -- Pacific Area -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Surgery -- Asia -- Periodicals; Heart -- Surgery -- Pacific Area -- Periodicals; Heart -- Surgery -- Periodicals; Chest -- Surgery -- Asia -- Periodicals; Chest -- Surgery -- Pacific Area -- Periodicals; Chest -- Surgery -- Periodicals; 617.412
• DOI: 10.1177/0218492316688416
• Languages: English
• ISSNs: 0218-4923

Abstract

Background: Coagulopathy is a major problem in surgery for cyanotic congenital heart disease. Tranexamic acid has been used both topically and systemically and plays a vital role in pediatric cardiac surgery by reducing blood loss and blood product requirement. We aimed to determine the anti-fibrinolytic effectiveness of low-dose systemic or topical tranexamic acid or a combination of both. Methods: Seventy-five patients were divided in 3 groups of 25. Group A patients were given tranexamic acid 20 mg kg −1 intravenously after sternotomy and 20 mg kg −1 after heparin reversal. Group B patients were given tranexamic acid 50 mg kg −1 in 20 mL of saline intrapericardially before sternal closure, with the drain clamped for 20 min. Group C patients were given tranexamic acid 20 mg kg −1 intravenously after sternotomy and 50 mg kg −1 intrapericardially before sternal closure. A number of clinical variables were recorded in the first 3 postoperative days. Ventilator time, intensive care unit stay, and outcome were also recorded. Results: Chest tube drainage and blood product requirements were lowest in group C. Blood urea and serum creatinine levels were higher in groups A and C ( p < 0.05). Intensive care unit stay and ventilator time were similar in all 3 groups. No patient died and none had a seizure or other neurological event or thromboembolic complication postoperatively. Conclusion: The combination of low-dose intravenous and topical tranexamic acid reduces postoperative blood loss and blood product requirement without incurring neurological, renal or thromboembolic complications. We recommend the routine use of topical and low-dose systemic tranexamic acid in cyanotic pediatric cardiac surgery.